Dark Forest Capital Management LP Invests $540,000 in United Therapeutics Co. (NASDAQ:UTHR)

Dark Forest Capital Management LP acquired a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,530 shares of the biotechnology company's stock, valued at approximately $540,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. World Investment Advisors LLC acquired a new stake in United Therapeutics in the third quarter worth about $393,000. Tidal Investments LLC raised its position in shares of United Therapeutics by 33.1% in the 3rd quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock valued at $4,039,000 after purchasing an additional 2,803 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in United Therapeutics in the 3rd quarter worth approximately $7,686,000. Franklin Resources Inc. grew its position in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Finally, Oddo BHF Asset Management Sas acquired a new position in United Therapeutics during the 3rd quarter valued at approximately $1,698,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at approximately $499,747.50. This trade represents a 63.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,500 shares of company stock valued at $24,472,050 in the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 1.9 %

United Therapeutics stock traded up $5.66 during mid-day trading on Monday, hitting $297.04. The company had a trading volume of 410,281 shares, compared to its average volume of 447,897. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 0.97 and a beta of 0.63. The company's fifty day moving average is $307.00 and its 200-day moving average is $346.00. United Therapeutics Co. has a 12-month low of $233.31 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the firm posted $4.36 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.